Shares of Achillion Pharmaceuticals, Inc. ACHN are trending higher on Monday following updated interim results from a Phase 2 study of its ACH-3102 treatment.
The company reported that “one hundred percent of patients (12/12) in the six-week treatment duration arm achieved SVR12, which included patients with high baseline viral load.”
Following the favorable announcement, shares of Achillion were up more than 14 percent Monday morning at $12.44.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in